News

Cardio-Oncology in China – A New Frontier!

Admin • CCON • 12/15/2016

From the first Cardio-Oncology workshop in June 2016 to a national meeting in November, the First Affiliated Hospital of Dalian Medical University in partnership with Peony Solutions, accelerates growth of... Read more »

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Admin • CCON • 7/31/2016

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy Canadian Journal of Cardiology, July 2016, Volume 32, Issue 7, Pages 831–841 Read Article Here

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter

Admin • CCON • 2/2/2016

Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article

Cardiac Meds Appear to Protect Heart From Herceptin Damage

Admin • CCON • 12/15/2015

SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart... Read more »

KU hospital program promotes heart health for cancer patients

Admin • CCON • 12/14/2015

KANSAS CITY, Kan. —A program at the University of Kansas Hospital is now combining cardiology and oncology. Read More

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »

Can cancer itself damage the heart?

Admin • CCON • 12/3/2015

Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »

Harwich Port woman blindsided by chemotherapy

Admin • CCON • 11/29/2015

Breast cancer was a devastating diagnosis for Kathleen Mingle, a teacher who played tennis, ran and generally led an active and fit life. But the shock was compounded when she... Read more »

CCC 2015: Improving Cardiac Care for Cancer Patients

Admin • CCON • 11/19/2015

CCS Position Statement Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society’s (CCS) first position statement on cardiovascular complications... Read more »